ENABLING REGENERATIVE
BIOLOGICS
Our regenerative technology is breaking the frontier in therapeutic and cosmetic applications.
VISION
Reinventing
The Way Forward
At Celligenics, we are reinventing the way forward by harnessing regenerative technology to support the body in repairing, regenerating, and restoring itself to a state of well-being.
INTRODUCING
CGN1
Our core technology is CGN1, a regenerative extract that harnesses stem cell secretions to stimulate cell repair and regeneration.
SOURCE
A unique sub-population of stem cells that embody the best qualities of embryonic and adult set cells without their down sides.
PURITY
Proprietary Process that extracts stem cells at a purity level of more than 90%, resulting in superior regenerative qualities.
CELL-FREE
By only using the secretions instead of the stem cells, the regenerative extract is cell-free, which reduces safety and ethical issues.
SCALABLE
Utilising the regenerative extract, with our optimised proprietary processes, allows greater scalability and cost-effectiveness.
PRODUCT
Platform
Technology
Our regenerative extract is a platform technology, with limitless application potential. Two product lines are currently under development, with more to come.
Wound Healing
Chronic ulcers are wounds that affect old, sick, or obese people with poor blood circulation. They do not heal on their own, and, even with treatment, the average chronic ulcer takes at least 3 months to heal.
Our regenerative extract, formulated with optimised stem cell secretions, can double the rate of wound healing, and as a result, reduce hospitalisation incidence, and lower treatment costs for patients.
DEVELOPMENT STATUS
Ready For Phase 1 Clinical Trials [2025]
.jpg)
Cosmeceuticals
Traditional skincare products lose their effectiveness over time, and stronger and more expensive products are then required to maintain the health of our skin.
From our regenerative extract, we have derived a skincare blend that contains biologically active ingredients that do not just make your skin look better temporarily, but create lasting changes in your skin.
DEVELOPMENT STATUS
Ready For Launch [2024]
Established in 2016, Celligenics is a spin-off of the Agency for Science, Technology & Research (A*STAR), Singapore’s leading public R&D agency, and one of A*STAR’s top 10 new biotech start-ups in 2018.
We are also a finalist for Singapore’s Emerging Enterprise Award 2021, the top business award jointly organised by OCBC Bank and The Business times that recognises the ambitions of emerging enterprises.
ABOUT US
A Singapore Biotechnology Company
TEAM
The People At Celligenics
Collectively, our core expertise spans across investment finance, enterprise strategy and product development, as well as experience in the field of working with molecular and cell biology.
Kurt WEE
Founder & CEO
Prof. David BECKER
Scientific Advisor
Dr. Pamela MOK
Scientific Director, Regenerative Technology
HUANG Ban Chin
Board Director
Prof. Amittha WICKREMA
Scientific Advisor
Winston LUMENTA
Head, Corporate Development
KOH Choon Hui
Board Advisor
Dr. John A. DANGERFIELD
Senior Director
PARTNERS
Our Collaborators
We leverage the strength of our strategic partnerships to accelerate innovative growth, find new audiences, and optimise our value chain.
WE INVITE YOU TO JOIN OUR ENDEAVOUR IN DELIVERING
INNOVATIVE SOLUTIONS THAT WILL BENEFIT EVERYONE.